Citing third-party data, Hettenback said downloads of the Hims & Hers apps increased 47% year over year in February. What it ...

BofA raised the firm’s price target on Hims & Hers to $22 from $21 and keeps an Underperform rating on the shares. February observed sales ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of ...

Citing third-party data, Hettenback said downloads of the Hims & Hers apps increased 47% year over year in February. On Apple's App Store, Hims & Hers offers two separate apps for download ...

On Apple's App Store, Hims & Hers offers two separate apps for download, "Hims," which advertises itself as an app for "hair loss, sexual health" and "Hers" which promotes "hair care, mental health." ...